CMTM4 and prostate adenocarcinoma: We found that CMTM4 expression was significantly higher in cholangiocarcinoma (CHOL), colon adenocarcinoma (COAD), esophageal carcinoma (ESCA), kidney chromophobe (KICH), pheochromocytoma and paraganglioma (PCPG), prostate adenocarcinoma (PRAD), rectum adenocarcinoma (READ), and thymoma (THYM) when compared to expression in normal tissues (Fig. 1A).